Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling(Ludwig-Maximilians-Universität München), Mats Jerkeman(Lund University), Simon Rule(University Hospitals Plymouth NHS Trust), Sanne H. Tonino(Amsterdam UMC Location University of Amsterdam), Marco Ladetto(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), John F. Seymour(The Royal Melbourne Hospital), Gilles Salles(Université Claude Bernard Lyon 1), Klaus Herfarth(Heidelberg University), Michele Ghielmini(Institute of Oncology Research)
Cited by 267
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907